Meeting
2022 ASCO Genitourinary Cancers Symposium
Interrelation of functional homologous recombination deficiency and hrr pathway alterations in prostate cancer.
Authors
Jason Zhu
Levine Cancer Institute, Atrium Health, Charlotte, NC
Jason Zhu , Sherif Mohamed El-Refai , Elizabeth Mauer , Benjamin D. Leibowitz , Landon Carter Brown , Claud Grigg , James T Kearns , Justin T. Matulay , Peter E Clark , Derek Raghavan , Earle F Burgess
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 151)
DOI
10.1200/JCO.2022.40.6_suppl.151
Abstract #
151
Poster Bd #
H9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2022 ASCO Genitourinary Cancers Symposium
Identification of homologous recombination and repair (HRR) deficiency using circulating tumor DNA (ctDNA) in advanced prostate cancer (aPC).
First Author: Leslie A. Bucheit
Poster
2023 ASCO Annual Meeting
Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.
First Author: Lorena Incorvaia